Decoy receptor 3: A pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer

Biochemical Pharmacology

Volumn 81, Issue 7, 2011, Pages 838-847

  Lin, Wan Wan ^a   Hsieh, Shie Liang ^b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Autoimmune; Cancer; Inflammation; TNF

Indexed keywords

ACTIN; BIOLOGICAL MARKER; DECOY RECEPTOR 3; DECOY RECEPTOR 3 IMMUNOGLOBULIN FC FRAGMENT; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; LIGHT PROTEIN; LYMPHOTOXIN BETA RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEOHEPARAN SULFATE; TUMOR NECROSIS FACTOR LIKE MOLECULE 1A; TUMOR NECROSIS FACTOR LIKE MOLECULE 1A ANTAGONIST; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNE DISEASE; CANCER CELL; CANCER INVASION; CELL ADHESION; CELL DIFFERENTIATION; COLLAGEN INDUCED ARTHRITIS; DCR3 GENE; DENDRITIC CELL; DISEASE MARKER; ENTERITIS; ENZYME INHIBITION; EPIGENETICS; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE FUNCTION; GRAFT REJECTION; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; KERATINOCYTE; KIDNEY DISEASE; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MONOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OVARY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SENSITIZATION; TESTIS; TH2 CELL; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GENE; TUMOR GROWTH; UPREGULATION;

AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; LIGANDS; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B;

EID: 79952575635     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.01.011     Document Type: Note

References (100)

1. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703. (Pubitemid 29003951)
2. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999;274:13733-6.
3. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002;16:479-92. (Pubitemid 34260924)
4. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 2000;97:1230-5. (Pubitemid 30080841)
5. Bridgham JT, Johnson AL. Characterization of chicken TNFR superfamily decoy receptors. DcR3 and osteoprotegerin. Biochem Biophys Res Commun 2003;307:956-61. (Pubitemid 36871665)
6. Liu L, Fujiki K, Dixon B, Sundick RS. Cloning of a novel rainbow trout (Oncorhynchus mykiss) CC chemokine with a fractalkine-like stalk and a TNF decoy receptor using cDNA fragments containing AU-rich elements. Cytokine 2002;17:71-81.
7. Tsutsui S, Yoshino Y, Matsui S, Nakamura O, Muramoto K, Watanabe T. Isolation of epidermal cells and cDNA cloning of TNF decoy receptor 3 of conger eel, Conger myriaster. Fish Shellfish Immunol 2008;24:366-71.
8. Inoue Y, Morinaga A, Takizawa F, Saito T, Endo M, Haruta C, et al. Molecular cloning and preliminary expression analysis of banded dogfish (Triakis scyllia) TNF decoy receptor 3 (TNFRSF6B). Fish Shellfish Immunol 2008;24:360-5.
9. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009;30:180-92.
10. Ware CF. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol Rev 2008;223:186-201. (Pubitemid 351986174)
11. Ware CF. Targeting the LIGHT-HVEM pathway. Adv Exp Med Biol 2009;647:146-55.
12. Sethi G, Sung B, Aggarwal BB. Therapeutic potential of VEGI/TL1A in autoimmunity and cancer. Adv Exp Med Biol 2009;647:207-15.
13. Bayry J. Immunology: TL1A in the inflammatory network in autoimmune diseases. Nat Rev Rheumatol 2010;6:67-8.
14. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003;15:185-93. (Pubitemid 38155825)
15. Whiteside TL. The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 2007;36:25-46. (Pubitemid 46028421)
16. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3:409-13. (Pubitemid 27145682)
17. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999;104:13-9. (Pubitemid 29534340)
18. Palao G, Santiago B, Galindo MA, Rullas JN, Alcami J, Ramirez JC, et al. Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis Rheum 2006;54:1473-81.
19. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998;8:21-30. (Pubitemid 28097820)
20. Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, et al. A lymphotoxin-beta-specific receptor. Science 1994;264:707-10. (Pubitemid 2070849)
21. Chen MC, Hwang MJ, Chou YC, Chen WH, Cheng G, Nakano H, et al. The role of apoptosis signal-regulating kinase 1 in lymphotoxin-beta receptor-mediated cell death. J Biol Chem 2003;278:16073-81. (Pubitemid 36799728)
22. Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, Flies D, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000;6:283-9. (Pubitemid 30148620)
23. Tumanov AV, Christiansen PA, Fu YX. The role of lymphotoxin receptor signaling in diseases. Curr Mol Med 2007;7:567-78. (Pubitemid 47618053)
24. Wang J, Fu YX. Tumor necrosis factor family members and inflammatory bowel disease. Immunol Rev 2005;204:144-55. (Pubitemid 40460499)
25. Lee WH, Kim SH, Lee Y, Lee BB, Kwon B, Song H, et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001;21:2004-10. (Pubitemid 34219754)
26. Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA, et al. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007;316: 285-8. (Pubitemid 46633106)
27. Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006;54:1451-62.
28. Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX. Contribution of the lymphotoxin beta receptor to liver regeneration. J Immunol 2005; 175:1295-300. (Pubitemid 41095019)
29. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 2004;64:1122-9.
30. Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, et al. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 2002;16:742-4.
31. Bamias G, Kaltsa G, Siakavellas SI, Papaxoinis K, Zampeli E, Michopoulos S, et al. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol 2010;137:242-9.
32. Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, Sfikakis PP. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol 2008;129:249-55.
33. Bamias G, Mishina M, Nyce M, Ross WG, Kollias G, Rivera-Nieves J, et al. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA 2006;103:8441-6. (Pubitemid 43838474)
34. Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005;14:3499-506. (Pubitemid 41672132)
35. Green DR. Apoptosis. Death deceiver. Nature 1998;396:629-30.
36. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001;61:2759-65. (Pubitemid 32685866)
37. Connolly K, Cho YH, Duan R, Fikes J, Gregorio T, LaFleur DW, et al. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J Pharmacol Exp Ther 2001;298:25-33.
38. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S, et al. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 2003;106:17-25. (Pubitemid 36750383)
39. Chen PH, Yang CR. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 2008;181:8441-9.
40. Zhang J, Salcedo TW, Wan X, Ullrich S, Hu B, Gregorio T, et al. Modulation of Tcell responses to alloantigens by TR6/DcR3. J Clin Invest 2001;107:1459-68. (Pubitemid 32522040)
41. Han B, Wu J. DcR3 protects islet beta cells from apoptosis through modulating Adcyap1 and Bank1 expression. J Immunol 2009;183:8157-66.
42. Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, et al. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 2002;168:4846-53. (Pubitemid 34495945)
43. Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, et al. Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 2005;175:5135-45. (Pubitemid 41456397)
44. Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW, Chen NJ, et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004;75:486-94. (Pubitemid 38316380)
45. Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 2008;111:5054-63.
46. Hsu MJ, Lin WW, Tsao WC, Chang YC, Hsu TL, Chiu AW, et al. Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp Cell Res 2004;292:241-51. (Pubitemid 38018840)
47. Yang CR, Hsieh SL, Ho FM, Lin WW. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol 2005;174:1647-56.
48. Tateishi K, Miura Y, Hayashi S, Takahashi M, Kurosaka M. DcR3 protects THP-1 macrophages from apoptosis by increasing integrin alpha4. Biochem Biophys Res Commun 2009;389:593-8.
49. Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 2004;11(Suppl. 1):S97-107.
50. Tang CH, Hsu TL, Lin WW, Lai MZ, Yang RS, Hsieh SL, et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem 2007;282:2346-54.
51. Wu YY, Chang YC, Hsu TL, Hsieh SL, Lai MZ. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3. J Biol Chem 2004;279:44211-8.
52. You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, et al. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 2008;111:1480-8.
53. Chang YC, Chan YH, Jackson DG, Hsieh SL. The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion. J Immunol 2006;176:173-80. (Pubitemid 43023261)
54. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, et al. Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol 2005;124:282-7. (Pubitemid 41060141)
55. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, et al. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 2002;5:61-8. (Pubitemid 34832239)
56. Ibrahim SM, Ringel J, Schmidt C, Ringel B, Muller P, Koczan D, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001;23:72-9. (Pubitemid 32592079)
57. Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol 2005;109:294-8. (Pubitemid 41166598)
58. Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008;10:1049-56.
59. Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol 2008;111:330-5.
60. Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett 2000;160:89-97.
61. Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, et al. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. Int J Oncol 2008;33:549-54.
62. Brunetti G, Oranger A, Mori G, Centonze M, Colaianni G, Rizzi R, et al. The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. Ann N Y Acad Sci 2010;1192:298-302.
63. Tu HF, Liu CJ, Liu SY, Chen YP, Yu EH, Lin SC, et al. Serum decoy receptor 3 level: a predictive marker for nodal metastasis and survival among oral cavity cancer patients. Head Neck 2011;33:396-402.
64. Chen G, Luo D. Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India 2008;21:275-8.
65. Kim S, Kotoula V, Hytiroglou P, Zardavas D, Zhang L. Significance of increased expression of decoy receptor 3 in chronic liver disease. Dig Liver Dis 2009;41:591-8.
66. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, et al. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 2003;105:724-32. (Pubitemid 36687744)
67. Chen J, Zhang L, Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 2004;285:63-70. (Pubitemid 38186586)
68. Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 2007;106:112-8.
69. Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, et al. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer 2002;102:254-7. (Pubitemid 35222293)
70. Shen HW, Gao SL, Wu YL, Peng SY. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 2005;11:5926-30.
71. Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, et al. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 2009;455:213-23.
72. Xiong G, Guo H, Wang K, Hu H, Wang D, Xu X, et al. Polymorphisms of decoy receptor 3 are associated with risk of esophageal squamous cell carcinoma in Chinese Han. Tumour Biol 2010;31:443-9.
73. Douet-Guilbert N, Lai JL, Basinko A, Gueganic N, Andrieux J, Pollet B, et al. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome. Br J Haematol 2008;143:716-20.
74. Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, et al. Overexpression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol 2000;119:323-7. (Pubitemid 30073037)
75. Kim S, McAuliffe WJ, Zaritskaya LS, Moore PA, Zhang L, Nardelli B. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun 2004;72:89-93. (Pubitemid 38018165)
76. Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U, Rogler G, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009;58:483-91.
77. Lee CS, Hu CY, Tsai HF, Wu CS, Hsieh SL, Liu LC, et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 2008;151:383-90.
78. Chen CC, Yang YH, Lin YT, Hsieh SL, Chiang BL. Soluble decoy receptor 3: increased levels in atopic patients. J Allergy Clin Immunol 2004;114:195-7.
79. Chen SJ, Wang YL, Kao JH, Wu SF, Lo WT, Wu CC, et al. Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells. Mol Immunol 2009;47:567-74.
80. Ka SM, Sytwu HK, Chang DM, Hsieh SL, Tsai PY, Chen A. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice. J Am Soc Nephrol 2007;18:2473-85. (Pubitemid 47378864)
81. Chen CY, Yang KY, Chen MY, Chen HY, Lin MT, Lee YC, et al. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit Care Med 2009;180:751-60.
82. Ho CH, Hsu CF, Fong PF, Tai SK, Hsieh SL, Chen CJ. Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter. J Virol 2007;81:4837-47.
83. Ho CH, Chen CL, Li WY, Chen CJ. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 2009;30:1443-51.
84. Kim S, Fotiadu A, Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol 2005;115:286-94. (Pubitemid 40712324)
85. Fayad R, Brand MI, Stone D, Keshavarzian A, Qiao L. Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells. Eur J Immunol 2006;36:2215-22. (Pubitemid 44251766)
86. Maeda T, Hao C, Tron VA. Ultraviolet light (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes. J Cutan Med Surg 2001;5:294-8. (Pubitemid 32843783)
87. Bobe J, Goetz FW. A tumor necrosis factor decoy receptor homologue is upregulated in the brook trout (Salvelinus fontinalis) ovary at the completion of ovulation. Biol Reprod 2000;62:420-6. (Pubitemid 30067345)
88. Chen HF, Chen JS, Shun CT, Tsai YF, Ho HN. Decoy receptor 3 expression during the menstrual cycle and pregnancy, and regulation by sex steroids in endometrial cells in vitro. Hum Reprod 2009;24:1350-8.
89. Sugimoto M, Kagawa N, Morita M, Kume S, Wongpanit K, Jin H, et al. Changes in the expression of decoy receptor 3 in granulosa cells during follicular atresia in porcine ovaries. J Reprod Dev 2010;56:467-74.
90. Gill RM, Coleman NM, Hunt JS. Differential cellular expression of LIGHT and its receptors in early gestation human placentas. J Reprod Immunol 2007;74:1-6. (Pubitemid 46679056)
91. Wu SF, Liu TM, Lin YC, Sytwu HK, Juan HF, Chen ST, et al. Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J Leukoc Biol 2004;75:293-306.
92. Wang YL, Chou FC, Sung HH, Fan PL, Hsueh CW, Lin WC, et al. Decoy receptor 3 protects non-obese diabetic mice from autoimmune diabetes by regulating dendritic cell maturation and function. Mol Immunol 2010;47:2552-62.
93. Sung HH, Juang JH, Lin YC, Kuo CH, Hung JT, Chen A, et al. Transgenic expressionof decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J Exp Med 2004;199:1143-51. (Pubitemid 38619910)
94. Kawamoto K, Tanemura M, Nishida T, Fukuzawa M, Ito T, Matsuda H. Significant inhibition of human CD8(+) cytotoxic T lymphocyte-mediated xenocytotoxicity by overexpression of the human decoy Fas antigen. Transplantation 2006;81:789-96.
95. Zhang J, Wang X, Fahmi H, Wojcik S, Fikes J, Yu Y, et al. Role of TL1A in the pathogenesis of rheumatoid arthritis. J Immunol 2009;183:5350-7.
96. Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, Elford C, et al. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med 2008;205:2457-64.
97. Ishida S, Yamane S, Ochi T, Nakano S, Mori T, Juji T, et al. LIGHT induces cell proliferation and inflammatory responses of rheumatoid arthritis synovial fibroblasts via lymphotoxin beta receptor. J Rheumatol 2008;35:960-8. (Pubitemid 351813137)
98. Mueller AM, Pedre X, Killian S, David M, Steinbrecher A. The decoy receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol 2009;209:57-64.
99. Kugathasan S, Baldassano RN, Bradfield JP, Sleiman PM, Imielinski M, Guthery SL, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 2008;40:1211-5.
100. Wroblewski VJ, McCloud C, Davis K, Manetta J, Micanovic R, Witcher DR. Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice. Drug Metab Dispos 2003;31:502-7. (Pubitemid 36378529)